ProShare Advisors LLC Grows Position in GE HealthCare Technologies Inc. $GEHC

ProShare Advisors LLC increased its position in GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 35.6% in the fourth quarter, HoldingsChannel reports. The firm owned 804,523 shares of the company’s stock after purchasing an additional 211,081 shares during the quarter. ProShare Advisors LLC’s holdings in GE HealthCare Technologies were worth $65,987,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. lifted its stake in shares of GE HealthCare Technologies by 0.5% in the 4th quarter. Vanguard Group Inc. now owns 52,275,767 shares of the company’s stock valued at $4,287,658,000 after purchasing an additional 267,058 shares during the period. Dodge & Cox lifted its stake in shares of GE HealthCare Technologies by 16.8% in the 3rd quarter. Dodge & Cox now owns 27,517,311 shares of the company’s stock valued at $2,066,550,000 after purchasing an additional 3,949,361 shares during the period. Capital Research Global Investors lifted its stake in shares of GE HealthCare Technologies by 25.0% in the 3rd quarter. Capital Research Global Investors now owns 24,972,556 shares of the company’s stock valued at $1,875,400,000 after purchasing an additional 4,998,154 shares during the period. Hotchkis & Wiley Capital Management LLC lifted its stake in shares of GE HealthCare Technologies by 17.1% in the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 8,432,374 shares of the company’s stock valued at $633,271,000 after purchasing an additional 1,232,828 shares during the period. Finally, Dimensional Fund Advisors LP lifted its position in GE HealthCare Technologies by 8.9% during the 3rd quarter. Dimensional Fund Advisors LP now owns 5,362,717 shares of the company’s stock valued at $402,647,000 after acquiring an additional 438,439 shares during the period. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Insiders Place Their Bets

In other GE HealthCare Technologies news, Director Watkin Phoebe L. Yang purchased 1,000 shares of the firm’s stock in a transaction dated Friday, May 8th. The stock was purchased at an average price of $63.01 per share, for a total transaction of $63,010.00. Following the completion of the purchase, the director directly owned 13,702 shares of the company’s stock, valued at $863,363.02. This trade represents a 7.87% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO James Saccaro purchased 3,310 shares of the firm’s stock in a transaction dated Friday, May 1st. The stock was acquired at an average price of $60.60 per share, with a total value of $200,586.00. Following the purchase, the chief financial officer directly owned 87,471 shares of the company’s stock, valued at approximately $5,300,742.60. The trade was a 3.93% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders bought 11,847 shares of company stock valued at $719,555. 0.36% of the stock is owned by company insiders.

GE HealthCare Technologies News Roundup

Here are the key news stories impacting GE HealthCare Technologies this week:

• Positive Sentiment: Argus kept a Buy rating on GE HealthCare while lowering its price target to $80 from $95, suggesting analysts still see upside from current levels despite trimming expectations. Article Link
• Neutral Sentiment: Another report said GE HealthCare is receiving an average analyst rating of Hold, which points to cautious sentiment but does not by itself change the investment case. Article Link
• Negative Sentiment: Kirby McInerney LLP said it is investigating potential claims involving GE HealthCare and possible violations of federal securities laws, adding to legal uncertainty for shareholders. Article Link
• Negative Sentiment: Bragar Eagel & Squire also said it continues investigating GEHC on behalf of stockholders, reinforcing the litigation overhang. Article Link
• Negative Sentiment: Glancy Prongay Wolke & Rotter announced a securities-fraud investigation into GE HealthCare, and Law Offices of Howard G. Smith separately launched a similar probe, increasing concerns about potential legal costs and reputational damage. Article Link Article Link

GE HealthCare Technologies Stock Up 0.1%

Shares of GE HealthCare Technologies stock opened at $61.56 on Wednesday. The company has a debt-to-equity ratio of 0.95, a quick ratio of 0.95 and a current ratio of 1.22. The stock has a market capitalization of $28.00 billion, a PE ratio of 14.73, a price-to-earnings-growth ratio of 1.38 and a beta of 0.74. GE HealthCare Technologies Inc. has a 52-week low of $58.75 and a 52-week high of $89.77. The company has a 50-day simple moving average of $69.02 and a two-hundred day simple moving average of $76.48.

GE HealthCare Technologies (NASDAQ:GEHC) last issued its earnings results on Wednesday, April 29th. The company reported $0.99 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.07 by ($0.08). The firm had revenue of $5.13 billion during the quarter, compared to analysts’ expectations of $5.04 billion. GE HealthCare Technologies had a return on equity of 20.46% and a net margin of 9.10%.The firm’s quarterly revenue was up 7.4% on a year-over-year basis. During the same period last year, the firm posted $1.01 earnings per share. GE HealthCare Technologies has set its FY 2026 guidance at 4.800-5.000 EPS. On average, analysts anticipate that GE HealthCare Technologies Inc. will post 4.89 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. JPMorgan Chase & Co. lowered their price target on shares of GE HealthCare Technologies from $80.00 to $65.00 and set a “neutral” rating for the company in a research report on Thursday, April 30th. The Goldman Sachs Group cut shares of GE HealthCare Technologies from a “buy” rating to a “neutral” rating and lowered their price target for the company from $81.00 to $65.00 in a research report on Thursday, April 30th. Barclays lowered their price target on shares of GE HealthCare Technologies from $87.00 to $78.00 and set an “equal weight” rating for the company in a research report on Thursday, April 30th. Mizuho lowered their price target on shares of GE HealthCare Technologies from $90.00 to $80.00 in a research report on Thursday, April 30th. Finally, HSBC lowered their price target on shares of GE HealthCare Technologies from $100.00 to $90.00 in a research report on Thursday, April 30th. Nine analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $80.63.

About GE HealthCare Technologies

GE HealthCare Technologies (NASDAQ: GEHC) is a global medical technology and diagnostics company that develops, manufactures and markets a broad range of products and services for healthcare providers. Its portfolio centers on diagnostic imaging systems, including MRI, CT, PET and X-ray modalities, as well as ultrasound equipment. The company also supplies patient monitoring and anesthesia delivery systems, interventional and surgical imaging solutions, and molecular imaging technologies used in both clinical care and research settings.

In addition to hardware, GE HealthCare offers software, analytics and lifecycle services aimed at improving clinical workflows and equipment uptime.